Cellvie
2 known investors
cellvie develops Therapeutic Mitochondria Transplantation, a technique that augments or replaces failing mitochondria to restore cellular energy metabolism, with initial applications in ischemia-reperfusion injury (starting with kidney transplantation) and in mitochondria-enabled gene therapy for the genetic skin disease Epidermolysis Bullosa. Its therapies target intractable human conditions including organ transplant injury, degenerative aging processes, and rare genetic diseases.
BiotechLongevityMedical Devices
Investors · 2
Frequently asked questions
- What does Cellvie do?
- cellvie develops Therapeutic Mitochondria Transplantation, a technique that augments or replaces failing mitochondria to restore cellular energy metabolism, with initial applications in ischemia-reperfusion injury (starting with kidney transplantation) and in mitochondria-enabled gene therapy for the genetic skin disease Epidermolysis Bullosa. Its therapies target intractable human conditions including organ transplant injury, degenerative aging processes, and rare genetic diseases.
- Who are Cellvie's investors?
- Cellvie's investors include Beiersdorf Innovation Fund, Taiho Ventures, LLC.